Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents

Oncologist

Volumn 16, Issue 1, 2011, Pages 71-81

  Ladoire, Sylvain ^a,b   Bonnetain, Franck ^c   Gauthier, Mélanie ^c   Zanetta, Sylvie ^a   Petit, Jean Michel ^b,d   Guiu, Séverine ^a   Kermarrec, Isabelle ^d   Mourey, Eric ^d   Michel, Frederic ^d   Krause, Denis ^d   Hillon, Patrick ^b,d   Cormier, Luc ^d   Ghiringhelli, François ^a,b   Guiu, Boris ^b,d  

^a Georges François Leclerc Center   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c EA 4184   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Antiangiogenic agents; Renal cell carcinoma; Visceral fat

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

AGED; ARTICLE; BODY MASS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAABDOMINAL FAT; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS FAT; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952581004     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0227     Document Type: Article

References (43)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-875.
2. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
4. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
5. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double- blind phase III trial. Lancet 2007;370:2103-2111.
6. Rini BI HS, Rosenberg JE et al. CALGB 90206: A phase III trial of bevacizumab plus interferon alpha versus interferon alpha monotherapy in metastatic renal cell carcinoma. Presented at the Genitourinary Cancers Symposium; San Francisco CA; February 14-16, 2008.
7. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
8. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-574.
9. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
10. Bergstrom A, Hsieh CC, Lindblad P et al. Obesity and renal cell cancer-a quantitative review. Br J Cancer 2001;85:984-990.
11. Chow WH, McLaughlin JK, Mandel JS et al. Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 1996;5:17-21.
12. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
13. Miyazawa-Hoshimoto S, Takahashi K, Bujo H et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003;46:1483-1488.
14. Silha JV, Krsek M, Sucharda P et al. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005;29:1308-1314.
15. Jacobsen J, Rasmuson T, Grankvist K et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-347.
16. Rioux-Leclercq N, Fergelot P, Zerrouki S et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38:1489-1495.
17. Guiu B, Petit JM, Bonnetain F et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based therapy in metastatic colorectal cancer. Gut 2010;59(3):341-347.
18. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.
19. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-841.
20. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110: 543-550.
21. Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113: 1552-1558.
22. Yoshizumi T, Nakamura T, Yamane M et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283-286.
23. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
24. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-5799.
25. Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 2004;160:1168-1176.
26. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563-576.
27. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007;117:2362-2368.
28. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006;28:737-745.
29. Rosendahl A, Forsberg G. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int J Oncol 2004;25: 1327-1336.
30. Kellerer M, von Eye Corleta H, Muhlhofer A et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 1995;62:501-507.
31. Suganami E, Takagi H, Ohashi H et al. Leptin stimulates ischemia induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004;53: 2443-2448.
32. Horiguchi A, Sumitomo M, Asakuma J et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006;176:1631-1635.
33. Attoub S, Noe V, Pirola L et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and racdependent signaling pathways. Faseb J 2000;14:2329-2338.
34. Brakenhielm E, Veitonmaki N, Cao R et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-2481.
35. Pinthus JH, Kleinmann N, Tisdale B et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008;54:866-873.
36. Rehman J, Traktuev D, Li J et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292-1298.
37. Kuk JL, Lee S, Heymsfield SB et al. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005; 81:1330-1334.
38. Chatterjee S, Kleinman N, Gharajeh A et al. Computerized tomography measurement of visceral adiposity predicts plasma adiponectin levels and metastatic disease in patients with clear cell renal cell carcinoma. Curr Urol 2008;2:188-193.
39. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000;1500:88-96.
40. Miyazawa-Hoshimoto S, Takahashi K, Bujo H et al. Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. Am J Physiol Endocrinol Metab 2005;288:E1128-E1136.
41. Negrier S, Chabaud S, Escudier B et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007;25(suppl):5044.
42. Bukowski R, Heng D, Eisen T et al. Sorafenib in advanced renal cell carcinoma (RCC): survival and biomarker results from a phase III trial. Eur Urol 2008;7(suppl):245.
43. Rupnick MA, Panigrahy D, Zhang CY et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002;99: 10730-10735.